mirvetuximab
immunogen
['ovarian', '$imgn']
$imgn is up 11.55% as immunogen's elahere shows overall survival benefit in phase 3 trial for platinum-resistant ovarian cancer. elahere could be the new standard of care for fr -positive patients. #asco 
Stock Market Trader - Follow your own opinions